What are the NCCN guidelines for neoadjuvant therapy for pancreatic cancer?

Updated: Oct 02, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

Like ESMO, NCCN recommends considering preoperative neoadjuvant therapy for patients with resectable or borderline resectable tumors, but notes that "there is limited evidence to recommend specific neoadjuvant regimens off-study, and practices vary with regard to the use of chemotherapy and radiation." NCCN recommendations on neoadjuvant therapy in pancreatic carcinoma are as follows [2] :

  • Consult with a high-volume center when neoadjuvant therapy is being considered\.
  • If neoadjuvant therapy is recommended, treat at or coordinate through a high-volume center, when feasible. 
  • Participation in a clinical trial is encouraged.
  •  Subsequent chemoradiation is sometimes included.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!